TY - JOUR T1 - Treatment Response to Hydroxychloroquine and Antibiotics for mild to moderate COVID-19: a retrospective cohort study from South Korea JF - medRxiv DO - 10.1101/2020.07.04.20146548 SP - 2020.07.04.20146548 AU - Min Ho An AU - Min Seo Kim AU - Yu-Kyung Park AU - Bong-Ok Kim AU - Seok Ho Kang AU - Won Jun Kim AU - Sung Kyu Park AU - Hea-Woon Park AU - Wonjong Yang AU - Joonyoung Jang AU - Soon-Woo Jang AU - Tae-Ho Hwang Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/07/2020.07.04.20146548.abstract N2 - Objectives To assess the efficacy of hydroxychloroquine on mild-moderate COVID-19 patients in South Korea.Methods A retrospective cohort study of the 358 laboratory-confirmed SARS-CoV-2 (COVID-19) patients was conducted. 226 patients met inclusion criteria for analysis. Propensity score matching (PSM) and Cox regression method were utilized to control and adjust for confounding factors. Mild to moderate COVID-19 patients were managed with hydroxychloroquine (HQ) plus antibiotics (n = 31) or conservative treatment (n = 195).Results Kaplan-Meier curves drawn using propensity score-matched data revealed no differences between the length of time to viral clearance and duration of hospital stay between the two treatment arms (p=0.18, p=0.088). Multivariable Cox regression analysis similarly showed that time to viral clearance(Hazard ratio (HR) 0.97, [95%-confidence interval (CI): 0.57-1.67]) and symptom duration(HR 1.05, [95%-CI: 0.62-1.78]) were not different between groups. No severe adverse event or death was observed in either group.Conclusions HQ with antibiotics was not associated with better clinical outcomes in terms of time to viral clearance, length of hospital stay, and duration of symptoms compared to conservative treatment alone. Large prospective randomized trials are necessary for definitive conclusions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo acknowledgements.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of Pusan National University Yangsan Hospital approved this study and granted a waiver of informed consent from study participants.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe research data that support the findings of this study are available from corresponding author upon reasonable request. ER -